Search clinical trials for: Hydrochloride anlotinib

Total 7934 results

Columbia University
Astellas Pharma Inc; Susan G. Komen Breast Cancer Foundation

Completed

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

Breast Cancer

United States
Genentech, Inc.

Completed

A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

Non-Small Cell Lung Cancer
Hoffmann-La Roche

Completed

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Neoplasms

Spain, Korea, Republic of, Netherlands, Denmark
Hoffmann-La Roche

Completed

A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

Non-Squamous Non-Small Cell Lung Cancer

Italy
Eli Lilly and Company

Completed

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Neoplasms

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Metastatic Squamous Neck Cancer With Occult Primary | Small Intestine Lymphoma | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Gastrointestinal Stromal Tumor | Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Tongue Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Tongue Cancer | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Nasopharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage... and other conditions

United States
Herlev Hospital
Roche Pharma AG; Bispebjerg Hospital; Copenhagen University Hospital at Herlev; Onxe...

Terminated

A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Denmark
Dartmouth-Hitchcock Medical Center
Genentech, Inc.; Ligand Pharmaceuticals

Completed

Study of Tarceva and Targretin in Stage I-II Lung Cancer

Carcinoma, Non-small-cell Lung

United States
Merck Sharp & Dohme LLC

Completed

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Breast Neoplasms | Carcinoma, Non-Small-Cell Lung
People's Hospital of Guangxi
Liuzhou Workers Hospital; Cancer Hospital of Guangxi Medical University; First... and other collaborators

Not yet recruiting

Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma

Glioblastoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Non Small Cell Lung Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); GlaxoSmithKline; Merck Sharp & Dohme LLC; Nova...

Completed

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Merck Sharp & Dohme LLC

Terminated

A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

Carcinoma, Non-Small-Cell Lung
Meir Medical Center

Completed

Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment

Non-Small Cell Lung Cancer

Israel
Sun Yat-sen University

Completed

A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung

Non-small Cell Lung Cancer

China
Translational Oncology Research International
National Cancer Institute (NCI)

Completed

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Head and Neck Cancer

United States
Yonsei University

Unknown

Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

Lung Cancer

Korea, Republic of
Novartis Pharmaceuticals

Completed

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Non Small Cell Lung Cancer

France, Canada, United States, Russian Federation, Denmark
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Mirati Therapeutics Inc.

Terminated

A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Advanced Malignancies, Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Neoplasms

United States
Syndax Pharmaceuticals

Completed

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma

United States
Washington University School of Medicine

Withdrawn

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Glioma | Osteosarcoma | Ependymoma | Medulloblastoma | Rhabdomyosarcoma | Wilms Tumor | Neuroectodermal Tumor | Ewing's Sarcoma
Louisiana State University Health Sciences Center...
Polyphenon E International,Inc.

Terminated

Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Chinese PLA General Hospital

Unknown

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Neoplasms, Lung | Carcinoma, Non-Small Cell Lung | Drug Therapy | Genes, EGFR

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Lung Cancer

United States
Second Affiliated Hospital of Nanchang University

Recruiting

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Immunotherapy | Tislelizumab | Pulmonary Pleomorphic Carcinoma

China
Samsung Medical Center
AstraZeneca

Unknown

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

EGFR Mutation Positive Non-small Cell Lung Cancer

Korea, Republic of
Medical University of South Carolina

Completed

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Liver Cancer

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer
The First Affiliated Hospital of Zhengzhou University
Anyang Tumor Hospital; Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia... and other collaborators

Recruiting

Novel Treatment of Advanced Hepatocellular Carcinoma (NTAHCC)

HCC

China
M.D. Anderson Cancer Center
Millennium: The Takeda Oncology Company

Completed

Study of Ixazomib and Erlotinib in Solid Tumors

Solid Tumors

United States
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Non Small Cell Lung Cancer
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Lithuania, South Africa, Slovenia, Italy, Canada, Belgium, Poland, Czech Republic and more
Spanish Lung Cancer Group
Merck Sharp & Dohme LLC

Terminated

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Non-small Cell Lung Cancer

Spain
Fudan University

Active, not recruiting

Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

Thyroid Cancer

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Eli Lilly and Company

Terminated

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Renal Cell Carcinoma | Metastases, Neoplasm | Neuroendocrine Tumors | Carcinoma, Non-small Cell Lung

France, United States
Southern Illinois University
Genentech, Inc.; OSI Pharmaceuticals

Completed

Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

Head and Neck Cancer

United States
National Taiwan University Hospital

Unknown

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca (Oncology)

Non-small Cell Lung Cancer(NSCLC)

Taiwan
Zhejiang Cancer Hospital

Unknown

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Non-small Cell Lung Cancer

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Esophageal Squamous Cell Carcinoma

China
Memorial Sloan Kettering Cancer Center
Ascenta Therapeutics

Terminated

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Taiwan
Hunan Province Tumor Hospital

Unknown

Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma

Lung Adenocarcinoma
National Cancer Institute (NCI)

Completed

Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States

Search clinical trials for: Hydrochloride anlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations